Dare Bioscience (DARE) Fundamentals 2026 — Revenue Analysis | SniperIQ
Dare Bioscience (DARE) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dare Bioscience's market cap?
Dare Bioscience (DARE) has a market capitalization of approximately
What is Dare Bioscience's P/E ratio?
Dare Bioscience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 24.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dare Bioscience?
Dare Bioscience runs a net profit margin of -1038.8%, a gross margin of -96.0%, and an operating margin of -1034.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dare Bioscience generate?
Dare Bioscience reported revenue of
Does Dare Bioscience pay a dividend?
Dare Bioscience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Dare Bioscience financially healthy?
Dare Bioscience carries a debt-to-equity ratio of 2.20x and a current ratio of 1.03x, with a market beta of 1.02. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dare Bioscience a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dare Bioscience (DARE) the key facts are: market cap
Track Dare Bioscience's full fundamentals live
Get Dare Bioscience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.